GSK prepares to go head-to-head with Merck

With a huge market at stake, GlaxoSmithKline says it will mount a head-to-head study of its cervical cancer vaccine Cervarix against Merck's Gardasil. The Phase III trial involves 1,042 volunteers in two arms, each taking one of the two vaccines. The trial will compare the immune response of 18 to 24-year-old women to two types of human papillomavirus. Secondary objectives are laid out for immune responses among older women.

- check out GSK's press release
- read the AFX report on the trial

PLUS: The Guardian covers the development of a new generation of virus-vectored vaccines that promise to take on a number of diseases like malaria. Report

Suggested Articles

Biogen unveiled full phase 1/2 for a prospect that emerged from a shift in its thinking about treating amyotrophic lateral sclerosis.

It took a little longer than expected, but Biogen’s done it—along with partner Eisai, the Big Biotech has completed an FDA filing for aducanumab.

Gilead is ditching a new avenue of treating hepatitis B as it cuts ties with Precision Biosciences less than two years into their research pact.